Sure.
With respect to the pharmacare program, I think any opportunity we have to increase access to safe and effective medications for children is a step in the right direction. We know that one in six families has struggled to fill prescriptions that have been directed for their children because of cost.
In terms of the safety and efficacy of the formulations themselves, 80% are prescribed off label, which means that it is not an approved, regulated dosage for a child or a youth. Safety and efficacy matter. Children have very specific sizes and develop at very specific stages and so it's not appropriate to look at an adult dosage and scale back. There are lots of challenges in terms of regulatory barriers for pharmaceutical companies to invest in the clinical trials for children, so that's an opportunity that the CPS has been leading in terms of regulatory reform for pharma.